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Abstract
Phage therapy offers a potential alternate strategy for the treatment of peri-prosthetic joint
infection (PJI), particularly where limited effective antibiotics are available. We undertook
preclinical trials to investigate the therapeutic efficacy of a phage cocktail, alone and in com-
bination with vancomycin, to reduce bacterial numbers within the infected joint using a clini-
cally-relevant model of Staphylococcus aureus-induced PJI. Infected animals were
randomised to 4 treatment groups, with treatment commencing 21-days post-surgery: bac-
teriophage alone, vancomycin alone, bacteriophage and vancomycin, and sham. At day 28
post-surgery, animals were euthanised for microbiological and immunological assessment
of implanted joints. Treatment with phage alone or vancomycin alone, led to 5-fold and 6.2-
fold reductions, respectively in bacterial load within peri-implant tissue compared to sham-
treated animals. Compared to sham-treated animals, a 22.5-fold reduction in S. aureus bur-
den was observed within joint tissue of animals that were administered phage in combina-
tion with vancomycin, corresponding with decreased swelling in the implanted knee.
Microbiological data were supported by evidence of decreased inflammation within the joints
of animals administered phage in combination with vancomycin, compared to sham-treated
animals. Our findings provide further support for phage therapy as a tolerable and effective
adjunct treatment for PJI.
Introduction
Bacteriophage, or phages, are naturally occurring, obligate predators of bacteria that were dis-
covered in the early 20th century [1]. Phage safety in humans is well documented with phage
therapy used in Eastern Europe for almost a century for the treatment of acute and chronic
bacterial infections [2–4]. The continued and rapid global emergence of antibiotic resistance
due to overuse and misuse prompted the recent World Health Organisation warning of this
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silent pandemic and its imminent dire implications without immediate changes to antimicro-
bial stewardship and identification of alternative treatment strategies [5]. Consideration of
phages as an alternate therapeutic approach for difficult to treat bacterial infections, including
osteomyelitis, has renewed over the past decade with an increase in the number of published
case reports of successful clinical outcomes following phage therapy [6, 7] and a small number
of clinical trials completed, or in progress, in the USA, United Kingdom and Australia (https://
anzctr.org.au/, https://clinicaltrials.gov/, and https://globalclinicaltrialdata.com/) [3, 7]. None-
theless, statistical evidence of phage therapy efficacy has been inconsistent with clinical trials
completed to date, prompting calls for continued translational research efforts in this field so
as to guide effective clinical practice in future [7].
Prosthetic joint infection (PJI) following total knee arthroplasty (TKA) remains the leading
cause for revision surgery, with methicillin-susceptible Staphylococcus aureus (MSSA) the bac-
terium most frequently responsible [8–10]. S. aureus biofilm formation is a key component in
the virulence armamentarium of this bacterium in the pathogenesis of PJI. Bio-inert orthopae-
dic materials such as titanium provide habitable substrates for biofilm formation, a growth
state which serves to facilitate bacterial survival in hostile environments [11, 12]. Not only
does the structure of the biofilm limit the penetration of antibiotics and immune mediators,
but recalcitrance to treatment is also driven by altered metabolic phenotype of bacterial cells
within the biofilm matrix [12–14]. Consequently, current surgical and antibiotic management
strategies for PJI are not only costly and traumatic for the patient, but also associated with con-
siderable morbidity and mortality with failure rates of 14.8% to 25% [8, 15–17].
In contrast to antibiotics which decrease in concentration below the surface of bacterial bio-
films, phages are capable of penetrating biofilms and self-replicating [2]. To overcome poten-
tial limitations arising from the high phage specificity, phage cocktails have been used to
broaden the spectrum of activity [2, 18, 19]. Recently, a French case series was published
describing the successful treatment of PJI caused by S. aureus with phages in combination with
antibiotics [18]. However, while the application of phages for the treatment of bone and joint
infections appears promising, detailed preclinical and clinical studies to evaluate their in vivo
efficacy are lacking. To our knowledge, there have been no preclinical studies using models
that are clinically representative of TKA to investigate phage as an adjunct therapy for PJI
caused by S. aureus.
Proof-of-principle in vitro studies demonstrated potential application of a lytic phage cock-
tail to reduce S. aureus numbers within biofilms growing on custom 3D-printed, miniaturized
porous titanium implants, a material commonly used in the manufacture of orthopaedic
implants [20]. Using the same titanium implants and additional biomaterials employed in
modern TKA, a novel rat model of S. aureus biofilm-associated PJI was also recently character-
ised [21]. The aim of the current study was to compare the in vivo efficacy of single or combi-
nation therapy using a bacteriophage cocktail and vancomycin for reducing S. aureus burden
within the implanted knee of the rat model of S. aureus biofilm-associated PJI. We hypothe-
sised that S. aureus burden will be reduced in peri-implant tissue from animals receiving bacte-
riophage therapy, and that combination therapy with bacteriophage and vancomycin will
further reduce bacterial load.
Materials and methods
Ethics statement
The care and use of all animals in this study was in strict accordance to the National Health
and Medical Research Council Australian Code for the Care and Use of Animals for Scientific
Purposes. All animal experimental procedures were approved by the James Cook University
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Institutional Animal Ethics Committee (A2326). Surgeries were performed under isoflurane
anaesthesia and animal sacrifice was performed by pentobarbital (100 mg/kg) overdose at des-
ignated end-points.
Microorganism and antimicrobial agents
A previously described MSSA clinical isolate, ORI16_C02N, recovered from a patient with
delayed-onset PJI following TKA was used in the current study [20]. A single stock preparation
was cultured overnight in tryptic soya broth (TSB), and stored in multiple, snap-frozen ali-
quots at -80˚C. Aliquots from this master stock were used for all animal infection experiments.
Sterile titanium implants were pre-seeded with S. aureus under in vitro conditions prior to
implantation into rat femurs, as described previously [21]. The mean bacterial density on each
implant at the time of surgery (day 0) was 1.2 x106 CFU (range, 8.9 x 105–1.9 x 106 CFU).
Five lytic S. aureus-specific phages (StaPh_1, StaPh_3, StaPh_4, StaPh_11 and StaPh_16) of
the family, Myoviridae, were used to prepare the StaPhage cocktail for the current study [20].
In vitro spot tests were performed to confirm bactericidal activity of each phage toward
OR16_C02N [20]. Individual phage suspensions contained 1 x 109−12 plaque-forming units
(PFU)/mL and were stored at 4˚C, with titres and sterility confirmed prior to each use. For
preparation of StaPhage cocktail, individual phage preparations were adjusted 5 x 108 PFU/mL
in sterile 0.9% saline, then combined at equal volumes to achieve a cocktail containing 2.5 x
109 PFU/mL. StaPhage cocktail was prepared immediately prior to administration to animals.
Vancomycin powder (Alphapharm, Sydney, Australia) was dissolved in sterile water and
administered intraperitoneally at a dose of 50 mg/kg, as described below. The sensitivity of
OR16_C02N to vancomycin was confirmed by the epsilometer (Etest) method (BioMe´rieux,
Norwest, Australia) prior to the experiment (minimum inhibitory concentration, MIC 1.8 μg/
mL).
Animals
Conventional, twenty-week-old male Sprague-Dawley rats (n = 47, 360 to 480 g) were used.
Animals were individually caged, fed a standard pellet diet and provided water ad libitum.
After a 7-day acclimation period, knee implant surgery was performed on rats under isoflur-
ane anaesthesia using surgical techniques and materials, as described previously [21]. Surgeries
were performed on 10 to 12 animals per surgery day. Prior to each surgery day, animals were
randomised to a treatment group, with equal numbers of animals per treatment group for
each surgery date. The order of animals undergoing surgery on each surgery day was also ran-
domised. Briefly, a UHXLPE implant was seated in a small mantle of gentamicin-laden bone
cement (Heraeus Palacos1 R+G, Zimmer Biomet, Sydney, Australia) within the proximal
tibia. A titanium implant, pre-seeded with S. aureus, was press-fit into a defect created in the
distal femur. Following implantation, the patella was repositioned, and the capsule and skin
closed. Immediately after skin closure and prior to recovery from anaesthesia, animals received
pre-emptive analgesic consisting of a 0.05 mg/kg subcutaneous injection of buprenorphine
(Temgesic1) in a 1mL bolus of saline. Post-operative analgesic (buprenorphine, 0.01–0.05
mg/kg) was administered at 6 and 12 hrs post-surgery, with analgesic administered 12 hourly
thereafter, according to pain scores of individual animals. Clinical signs including body weight,
temperature and weight-bearing activity were monitored daily throughout the experimental
period. Establishment of infection was confirmed by differential white blood cell at day 5 post-
surgery (S1 Table) [21]. Animals were sacrificed at 28 days post-surgery (7 days after com-
mencing treatment) with an overdose of pentobarbital (100 mg/kg) for gross pathology,
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haematology, microbiology, inflammatory, and histological evaluation. All animal experimen-
tal procedures were approved by the Institutional Animal Ethics Committee (A2326).
Treatment
At commencement of the 7-day acclimation period prior to surgery, animals were randomised
to the following treatment groups: no treatment (Sham, n = 12), phage alone (Ph, n = 12), van-
comycin alone (V, n = 11), phage plus vancomycin (Ph+V, n = 12) (Fig 1). Normal (0.9%) ster-
ile saline was administered to sham-treated controls via the intraperitoneal (i.p.) route on day
21, 22 and 23 post-surgery. StaPhage cocktail (1.3 x 108 PFU; multiplicity of infection (MOI),
> 104 PFU:1 CFU) was administered via the i.p. route on day 21, 22 and 23 post-surgery. Van-
comycin (50 mg/kg, i.p.) was administered from day 21 to 27 post-surgery every 12 h [22–24].
Animals receiving combination therapy were administered phage and vancomycin in accor-
dance with the single therapy regimens.
Haematology and inflammatory assessments
Blood was collected under anaesthesia via the lateral tail vein during the experimental period
and via terminal cardiac puncture at day 28 post-surgery (Fig 1). Complete blood cell examina-
tion (CBE) was carried out using an automated ACT Diff analyser (Beckman Coulter, Brea
CA, USA). Blood samples were centrifuged, and plasma collected and stored at -80˚C until
analysis. C-reactive protein (CRP) was measured in plasma using a Rat C-reactive protein
ELISA (BD Biosciences, North Ryde, Australia) and calprotectin was measured in joint tissue
homogenates using a Rat Calprotectin ELISA (Cusabio, Houston, TX, USA), according to
manufacturer protocols. Inflammatory chemokines and cytokines (MCP-1, GRO/KC, MIP-2,
TNF-a, IL-1ß, IL-6, IL-12p70, IFN-g, IL-4, IL-10) were measured in plasma and joint tissue
homogenates using Milliplex1 Rat Cytokine/Chemokine Magnetic Bead Panel (RECYT-
MAG-65K, Lot #3070574 and #2927420, Abacus ALS, Meadowbrook, Queensland) in combi-
nation with the Magpix1 analyser (Luminex Corporation, Austin, Texas, USA). Assays were
carried out according to manufacturer’s instructions with samples measured in duplicate.
Fig 1. Schematic representation of the study protocol for evaluation of bacteriophage therapy in a rat model of S. aureus
biofilm-associated PJI. Blood sampling via the lateral tail vein (indicated by droplet) was performed 1 day prior to surgery, and at
day 5, 20 and 28 post-surgery. End-point analyses were performed at day 28 post-surgery (7 days after commencement of
treatment).
https://doi.org/10.1371/journal.pone.0226574.g001
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Microbiological analyses
Bacterial loads were determined in blood, tissues and implants from animals at day 28 post-
surgery, using methods described previously [21]. Briefly, liver, spleen, popliteal and inguinal
(draining) lymph nodes of the operated (right leg) and non-operated (left leg) limb were dis-
sected aseptically and weighed. The operated limb was also removed at the hip and soft tissue
dissected from the femur and tibia. Bone cuts were made approximately 2.5 cm proximal to
knee on femur and 2.5 cm distal on tibia. Titanium and UHXLPE implants were removed and
sonicated as described previously Lytic bacteriophages replicate within a specific host bacte-
rium causing lysis and death of the bacterial cell and release of phage progeny which perpetu-
ate the cycle as long as live bacterial target cells are present., with UHXLPE implants removed
from bone cement mantles prior to sonicating. After removal of implants, distal femur and
proximal tibia pieces were weighed, pulverised and homogenised in sterile phosphate buffered
saline (PBS, pH 7.2) [21]. In consideration of the potential for inadvertent haematogenous
seeding of implants by respiratory or gut flora following surgical stress in the animals, tissue
homogenates and implant sonicates were serially diluted in sterile PBS and cultured in tripli-
cate on both selective (mannitol salt agar, MSA) and non-selective (tryptic soy agar, TSA) agar
overnight to assess purity and to observe any phenotypic changes in colony morphology of the
S. aureus isolates recovered from the infected joints. The limit of detection for viable counts
was<5 CFU. Data is expressed as mean log10 CFU/total tissue or mean log10 CFU, as
indicated.
Antimicrobial sensitivity
Vancomycin and StaPhage sensitivity was determined for S. aureus (5–10 colonies) recovered
from femur and titanium implants of treated and untreated animals at day 28 post-surgery.
The susceptibility of the stock (pre-implantation) strain of ORI16-02N and isolates recovered
from animals (n = 8 animals per treatment group) toward the individual phages and the StaPh-
age cocktail was tested using standard spot tests, as described previously [20]. Briefly colonies
were recovered from TSA with a sterile cotton-tip swab, suspended in sterile TSB with 20%
glycerol (v/v) and aliquots snap-frozen at -80˚C. To assess antimicrobial sensitivity, single-use
aliquots were thawed, diluted in sterile TSB (1:5) and grown to log-phase (3 h, 37˚C, 100 rpm)
prior to preparation of bacterial lawns on TSA. Bacterial sensitivity to phage was considered
where confluent, semi-confluent, opaque lysis or individual plaques were observed in the bac-
terial lawn. A semi-quantitative scoring system (S1 Fig) was used to enable comparison of
phage sensitivity between isolates where: 0 = no plaques, 1 =< 10 individual plaques, 2 = 11–
100 individual plaques, 3 = partial clearing, >100 plaques, 4 = clearing with several distinct
bacterial colonies within the clearance zone, 5 = complete clearing. Vancomycin susceptibility
of S. aureus recovered from femur and titanium implants was compared to the pre-implanta-
tion S. aureus strain using the Etest method, and according to manufacturer protocols.
Statistics
Statistical analyses were performed using GraphPad Prism for Mac software (version 7). Data
normality was assessed using Shapiro-Wilks test, with Levene’s test used to determine equality
of variances. Non-normally distributed data was compared using a Mann-Whitney U test or
Kruskal-Wallis test with Dunn’s post-hoc analysis. Changes in haematology parameters
between groups were compared using two-way repeated measures ANOVA, with Holm-Sidak
post-hoc analysis. Within group differences were analysed with repeated measures ANOVA
with Dunnet’s post-hoc analysis. MILLIPLEX Analyst 5.1 software (Luminex Corporation,
Austin, Texas, USA) was used to determine cytokine and chemokine concentrations with a
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5-parametric logistic weighted curve fit. Results are expressed as mean ± standard deviation
(SD) unless otherwise stated, with significance set at P < 0.05.
Results
Clinical outcomes
All animals survived surgery and the postoperative period with no signs of systemic illness.
Administration of analgesic was ceased by day 5 post-surgery for all animals based on
improved clinical scores. Body temperature increased significantly between baseline and day 5
post-surgery for all animals, though levels remained within normal ranges throughout the
experimental period with no discernible effects of treatment on body temperature (S1 Table)
[21]. Animals were able to bear partial weight within 48 h of surgery. The median time to full
weight bear was 18 days post-surgery, with 12 of 47 animals not returning to full weight-bear-
ing within the 28-day experimental period. No significant difference was observed in the time
for sham-treated animals (median 21 d, range 10–28 d), or animals treated with phage alone
(median 18 d, range 13–28 d), vancomycin alone (median 17 d, range 11–28 d) or combined
phage and vancomycin (median 18 d, range 11–28 d) to return to full weight bearing following
surgery.
Minor weight loss was observed for all animals in the first week following surgery, however
body weight increased thereafter (S1 Table). Compared to sham-treated controls, body weight
was significantly lower in animals treated with phage alone, vancomycin alone and phage plus
vancomycin at day 28 post-surgery, despite comparable pre-treatment weights at day 20 post-
surgery (S1 Table).
Haematology and systemic inflammation
There were no statistically significant differences in haematology parameters between treat-
ment groups at baseline, or throughout the experimental period (S1 Table). While significant
changes were observed in erythrocyte, leucocyte and platelet parameters for all animals follow-
ing surgery, numbers tended to return to pre-surgical levels by the end of the experimental
period, consistent with previous findings in this infection model [21]. Establishment of infec-
tion was confirmed for all animals by a significant increase in the percentage of neutrophils at
day 5 post-surgery as previously described [21]. Similarly, plasma CRP concentrations were
significantly increased at day 5 post-surgery for all animals, though concentrations returned to
baseline levels by day 20 post-surgery and were comparable between treatment groups at day
28 post-surgery (S1 Table). Plasma lactate concentrations (indirect marker of tissue hypoxia)
were significantly increased at day 28 post-surgery compared to pre-surgical levels for all treat-
ment groups however, no significant between-group differences observed (S1 Table).
Plasma inflammatory chemokine and cytokine levels were comparable between treatment
groups at day 28 post-surgery (7 days after commencing treatment; Fig 2). TNF-a and IFN-g
levels remained below the assay limit of detection for all animals (<2.4 pg/ml and<14.6 pg/
ml, respectively). No significant differences were observed between sham-treated and phage-
treated animals for any of the inflammatory mediators measured at day 28 post-surgery. Com-
pared to sham-treated animals, plasma IL-10 levels were significantly higher in animals treated
with vancomycin alone and combined phage and vancomycin at day 28 post-surgery (p = 0.04
and p = 0.001, respectively; Fig 2E). Similarly, MCP-1 levels were significantly elevated in
plasma from vancomycin-treated animals compared to sham-treated controls (p = 0.018; Fig
2A). No significant differences were observed in IL-6, IL-1ß and IL-4 concentrations in plasma
of vancomycin-treated and phage plus vancomycin-treated animals at day 28 post-surgery
compared to sham-treated controls (Fig 2B, 2C and 2F).
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Joint swelling and pathology
Surgical incisions healed without complication in all animals. Joint circumferences of
implanted knees were comparable between sham-treated, phage-treated and vancomycin-
treated animals (Fig 3A). Compared to treatment with phage alone, the joint circumference of
implanted knees was significantly less for animals receiving combination therapy (p = 0.016;
Fig 3A). Upon dissection, macroscopic examination of the operated knees of animals at day 28
post-surgery revealed mild to severe soft tissue and articular cartilage damage, often in combi-
nation with increased amount and viscosity of synovial fluid (Fig 3B). A numerical scoring sys-
tem was used for semi-quantitative evaluation of gross pathology within operated joints of
animals at day 28 post-surgery, where 1 = mild soft tissue and articular cartilage damage and
Fig 2. Systemic inflammatory mediators. Concentrations of MCP-1, IL-1ß, IL-12p70, IL-6, IL-10 and IL-4 were
measured in plasma of sham-treated (Sham, n = 10) and treated (Ph, phage alone, n = 8; V, vancomycin alone, n = 8;
Ph+V, phage plus vancomycin, n = 9) at day 28 post-surgery (7 days after commencement of treatment). Data shows
mean ± SD. �P< 0.05.
https://doi.org/10.1371/journal.pone.0226574.g002
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the absence of synovial effusion; 2 = moderate soft tissue changes, synovial thickening, occa-
sional focal damage to articular cartilage with synovial effusion; and 3 = severe and extensive
soft tissue damage, synovial thickening, articular cartilage damage and synovial effusion with
Baker’s cyst (Fig 3B). No significant differences were observed in joint pathology between
treatment groups, though there was a trend for reduced tissue damage within joints from ani-
mals that received combination therapy (p = 0.13; Fig 3C).
Joint bacterial loads
Seven days after commencement of antimicrobial therapy, peri-implant joint tissue (femur,
tibia, patella and associated tendons, joint capsule tissues) and implants (titanium, UHXLPE)
were harvested for enumeration of bacteria (Fig 4, Table 1). Peri-implant tissue weights were
comparable between sham-treated (3.0 ± 0.5 g), and phage alone (3.0 ± 0.4 g), vancomycin
alone (2.9 ± 0.3 g), and phage plus vancomycin (2.8 ± 0.4 g) treated animals (p = 0.632). Sham-
treated animals had 8.1 x 104 ± 2 x 105 CFU (range, 8 x 101–7 x 105 CFU) in peri-implant joint
tissue, and 3.7 x 104 ± 9.4 x 104 CFU (range, 1.5 x 102–3.3 x 105 CFU) recovered from titanium
implants (12 of 12 animals). Treatment with phage alone resulted in 1.6 x 104 ± 2.9 x 104 CFU
(p = 0.100; 5-fold reduction; range, 0–8 x 104 CFU) in peri-implant tissue and 6 x 103 ± 1 x 104
CFU (p = 0.947; 6.2-fold reduction; range, 1.2 x 102–3.7 x 104 CFU) from titanium implants.
Animals treated with vancomycin alone had 1.3 x 104 ± 1.9 x 104 CFU from peri-implant tissue
(p = 0.235; 6.2-fold reduction; range, 0–5.5 x 104 CFU) and 1.9 x 104 ± 5.2 x 104 CFU from tita-
nium implants (p = 0.921; 1.9-fold reduction; range, 2.3 x 102–1.8 x 105 CFU). Combination
therapy with phage and vancomycin significantly reduced S. aureus numbers to 3.6 x 103 ± 5.8
x 103 CFU (p = 0.014; 22.5-fold reduction; range, 0–1.6 x 104 CFU) in peri-implant tissue.
However, mean bacterial load on titanium implants was comparable to those in sham-treated
animals (p = 0.852; 3.7 x 104 ± 6.1 x 104 CFU; range, 4.1 x 101–1.6 x 105 CFU). S. aureus was
recovered from sonicated UHXLPE implants in sham-treated (4 of 12), phage alone (4 of 12),
vancomycin alone (5 of 11), and phage plus vancomycin combination therapy (3 of 12). No
significant differences were observed between mean bacterial numbers recovered from
UHXLPE implants between treatment groups though numbers tended to be lower from ani-
mals treated with phage plus vancomycin, compared to sham-treated control animals
(p = 0.365, Fig 4C; Sham, 2.7 x 102 ± 9.1 x 102 CFU v Ph+V, 4.4 x 100 ± 8.8 x 100 CFU).
S. aureus was recovered from the femur (12 of 12), tibia (10 of 12), patella and associated
tendons and capsular tissue (9 of 12) of sham-treated animals at day 28 post-surgery (Table 1).
In contrast, compared with sham-treatment, fewer animals were positive for S. aureus in tibia
(ns, p = 0.098; 1.8-fold decrease), patella and joint soft tissue (p = 0.025; 4-fold decrease) fol-
lowing combination-therapy (Table 1).
Effect of antimicrobial therapy on local inflammatory responses
Joint tissue concentration of calprotectin, an indirect marker of neutrophil infiltration, was
comparable between sham-treated and single and combination therapy groups at day 28 post-
surgery (Fig 5A). No significant differences were observed between sham-treated and phage
Fig 3. Joint swelling and pathology. A) Joint circumference of the operated (implant) limb of infected and sham-
treated (Sham, n = 12), and those treated with phage alone (Ph, n = 12), vancomycin alone (V, n = 11) and phage plus
vancomycin (Ph+V, n = 12) at day 28 post-surgery. Data shows mean ± SD. �P< 0.05 B. Representative images of mild
(1), moderate (2) and severe (3) joint pathology changes in the operated hind limb of infected animals at day 28 post-
surgery. Based on this scoring system, C) gross joint pathology scores were compared for sham-treated (Sham), and
those treated with phage alone (Ph), vancomycin alone (V) and phage plus vancomycin (Ph+V) at day 28 post-surgery
(7 days after commencement of treatment). Data shows median ± interquartile range.
https://doi.org/10.1371/journal.pone.0226574.g003
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alone treated animals for any of the inflammatory markers assayed. Compared to sham-treated
animals and animals treated with phage alone, MCP-1 was significantly lower in joint tissue of
animals treated with phage plus vancomycin at sacrifice (p = 0.0001 and p = 0.0002 respec-
tively; Fig 5B). While differences were not statistically significant, there was a trend for
decreased concentrations of MCP-1 in joint tissue from vancomycin alone treated animals
(p = 0.06). Concentrations of TNF-a, IL-1ß, IL-6 and IL-4 were comparable between sham-
treated, phage alone, vancomycin alone and phage plus vancomycin treatment groups (Fig 5C,
5D, 5E and 5I). Compared to sham-treated and animals treated with phage alone, significantly
increased IL-12p70 (p = 0.033 and p = 0.003, respectively), IFN-g (p = 0.007 and p = 0.008,
respectively) and IL-10 (p = 0.004 and p = 0.002) levels were measured in joint tissue from ani-
mals treated with vancomycin alone (Fig 5F, 5G and 5H).
Development of antimicrobial resistance
Phage sensitivity was assessed to determine whether isolates recovered from the femur and
excised titanium implants of animals (n = 8 per treatment group) at day 28 post-surgery were
as susceptible as the original pre-inoculating S. aureus strain (S2 Table). StaPhage cocktail sen-
sitivity of all S. aureus strains recovered from bone and titanium implants was comparable to
that of the original, pre-implantation strain. However, screening of individual phage prepara-
tions identified phage-resistant colonies for isolates recovered from the femur of animals
treated with phage alone, compared to the original S. aureus strain for StaPh_4, StaPh_11, and
StaPh_16 (S2 Table). StaPh_1- and StaPh_3-resistant colonies were also observed for isolates
recovered from bone and implants of sham-treated animals and animals that had been treated
with vancomycin alone or phage plus vancomycin, respectively (S2 Table). No significant dif-
ferences were observed in the sensitivity of S. aureus isolates from sham-treated and phage
alone-treated animals toward StaPhage cocktail (p = 0.608), StaPh_1 (p> 0.999), StaPh_3
(p = 0.315), StaPh_4 (p = 0.132), StaPh_11 (p> 0.999), StaPh_16 (p> 0.999) (S2 Table).
Fig 4. The effect of single and combination antimicrobial therapy on S. aureus numbers in implanted knees.
Phage alone (Ph, n = 12), vancomycin (V, n = 11) or phage plus vancomycin (Ph+V, n = 12) was administered
intraperitoneally to rats from day 21 post-surgery. Sham-treated (Sham) animals were administered an equivalent
volume of sterile 0.9% saline. Peri-implant joint and bone tissue and implants were harvested from animals 7 days after
commencement of antimicrobial therapy (28 days post-surgery) for enumeration of bacteria. The mean CFU count for
the A) peri-implant tissue homogenates for the entire joint (a sum of the femur, tibia, patella and surrounding capsular
tissue) following removal of implants, B) the titanium implants and C) the UHXLPE implants was determined for each
treatment group. Data shows log10 CFU/tissue and log10 CFU/implant ± SD. �P< 0.05 compared to sham-treated
animals.
https://doi.org/10.1371/journal.pone.0226574.g004
Table 1. Proportions of S. aureus positive cultures within the joint by specimen type and treatment group.
Treatment Group No. of positive cultures/Total number of samples
Femur Tibia Patella^
Sham 12/12 (100) 10/12 (83) 9/12 (75)
Ph 9/12 (75) 7/12 (58) 7/12 (58)
V 10/11 (91) 9/11 (82) 4/11 (36)
Ph+V 10/12 (83) 5/12 (42) 2/12� (17)
Number and percentage of joint tissue samples from which S. aureus was recovered at day 28 post-surgery in sham-
treated (Sham), and those treated with phage alone (Ph), vancomycin alone (V) and phage plus vancomycin (Ph+V).
^includes surrounding tendons and capsular tissue. Statistical analyses were conducted using the Chi-square test.
�P < 0.05 compared to sham-treated.
https://doi.org/10.1371/journal.pone.0226574.t001
Bacteriophage for treatment of peri-prosthetic joint infection
PLOS ONE | https://doi.org/10.1371/journal.pone.0226574 December 26, 2019 11 / 18
Within each treatment group, there was also no significant difference in phage sensitivity
between strains recovered from bone and those from the titanium implant (S2 Table).
Vancomycin susceptibility of bacterial isolates recovered from the peri-implant tissue of the
femur and the titanium implants of sham-treated animals (n = 8) and animals treated with
phage alone (n = 7), vancomycin alone (n = 7) or phage plus vancomycin (n = 7) at day 28
post-surgery was compared to the inoculating strain of S. aureus (Fig 6). The MIC for ORI-
16C02N (n = 5 independent tests) prior to implantation in the rat model of PJI was 1.8 μg/ml.
The MIC for the majority of S. aureus isolates recovered from peri-implant tissue of sham-
treated (p = 0.008), and animals treated with vancomycin alone (p = 0.02) and phage plus van-
comycin (p = 0.03) were significantly higher than pre-infection levels. Similarly, significantly
increased MICs were observed for S. aureus isolates recovered from titanium implants of
sham-treated (p = 0.02), and animals treated with vancomycin alone (p = 0.02) and phage plus
vancomycin (p = 0.03) compared to pre-infection levels. However, no significant differences
Fig 5. Inflammatory mediators in joint tissue. Concentrations of calprotectin, MCP-1, TNF-a, IL-1ß, IL-12p70, IFN-g, IL-6, IL-10 and IL-4 were measured in joint tissue
of implanted knees of sham-treated (Sham, n = 10) and animals treated with phage alone (Ph, n = 10), vancomycin (V, n = 10) or phage plus vancomycin (Ph+V, n = 10)
at day 28 post-surgery (7 days after commencement of treatment). Data shows mean ± SD. �P< 0.05.
https://doi.org/10.1371/journal.pone.0226574.g005
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were observed between vancomycin susceptibility of isolates from treated and untreated ani-
mals. Furthermore, in vitro vancomycin sensitivities were comparable between isolates recov-
ered from peri-implant tissue and the surface of titanium implants within each treatment
group (Fig 6).
Discussion
As a looming post-antibiotic era threatens to undo a century of infectious diseases advance-
ments, increasing consideration is once again being given to phages as an alternative approach
for treating bacterial infections [3, 5]. Lytic bacteriophages replicate within a specific host bac-
terium causing lysis and death of the bacterial cell and release of phage progeny which perpetu-
ate the cycle as long as live bacterial target cells are present. Due to the absence of cytotoxic
effects toward mammalian cells, their high specificity, and their ability to infect bacterial cells
within biofilms, phages could potentially be used as an adjunct to antibiotics for treatment of
biofilm-associated PJI, although to date, preclinical studies evaluating their in vivo efficacy
have been lacking [1–3, 18, 25]. Using a clinically-relevant rat model of S. aureus biofilm-asso-
ciated PJI following TKA, we show several key findings in the present study. Firstly, the combi-
nation of phages with vancomycin exerted a significantly increased therapeutic benefit
compared to single therapy. Secondly, phage therapy alone tended to reduce bacterial burden
within joint tissue and on the titanium implant of the infected knee within one week of com-
mencing treatment, though this did not reach statistical significance. Thirdly, no adverse local
or systemic inflammatory effects were observed following administration of several doses of
relatively high numbers of lytic phages. Finally, S. aureus isolates recovered from the infected
knee of animals that received phage therapy remained susceptible to the five-phage cocktail.
The model used in the present study is clinically representative of delayed-onset PJI, where
implant-associated biofilms and progressive inflammatory responses and tissue remodelling
occur in peri-implant tissue over a period of weeks following surgery [21]. Though demand-
ing, it is an appropriate translational model for evaluating in vivo antimicrobial efficacy against
Fig 6. In vitro vancomycin susceptibility of S. aureus isolates recovered from the peri-implant tissue. In vitro
vancomycin susceptibility of S. aureus isolates recovered from the femur (F) and the titanium implants (Ti) of sham-
treated animals (Sham, n = 8) and animals treated with phage alone (Ph, n = 7), vancomycin alone (V, n = 7) or phage
plus vancomycin (Ph+V, n = 7) at day 28 post-surgery was compared to the inoculating strain of S. aureus (dotted red
line, n = 5 individual tests, mean MIC = 1.8 μg/ml). Data shows median ± interquartile range.
https://doi.org/10.1371/journal.pone.0226574.g006
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biofilm-associated PJI. Our data support synergism between phages and vancomycin, leading
to significantly reduced bacterial burden within joint tissue within 7 days of commencing
treatment. While not statistically significant, the trend observed for decreased bacterial num-
bers on titanium implants from animals exposed to phage alone may hold clinical significance.
Immune cell infiltration was not directly measured in the present study however, levels of
IFN-g, IL-12p70 and IL-10 in joint tissue of animals treated with vancomycin alone were sig-
nificantly higher than in sham- and phage alone-treated animals, suggesting that bacterial
reduction observed in this group was associated with increased activation of cell-mediated
immune responses. In contrast, the similarities between calprotectin (indirect marker of neu-
trophil infiltration) and inflammatory mediator concentrations within peri-implant tissue
from sham- and phage alone-treated animals suggests the reduction in bacterial load is directly
attributed to bactericidal activity of phages, rather than immune activation per se.
Vancomycin pharmacokinetics in rodents have previously been described [26], and the
dose used in the present study is sufficient to significantly reduce S. aureus numbers in experi-
mental models of chronic osteomyelitis [22–24]. There is currently no standard regimen for
phage administration for treatment of PJI. Previous experimental studies evaluating phage
therapy for osteomyelitis have used doses of 107−109 PFU administered daily for 3 to 8 days
[19, 27, 28]. We therefore chose to administer over 3 consecutive days, using a phage cocktail
containing a high dose of phage (>108 PFU). However, the effectiveness of phage therapy is
dependent on the phage reaching the site of infection. Difficulties with eradication of chronic
PJI arise due to poor vascular perfusion of ischaemic bone, the accumulation of peri-implant
necrotic and fibrotic tissue and formation of sequestra which impede penetration of antimi-
crobials to the implant-associated biofilm [21, 29, 30]. It is possible that an extended therapeu-
tic regimen may have led to further reduction in bacterial burden. The mechanisms
underlying phage-antibiotic synergy and how these interactions evolve during the course of
therapy and influence clinical outcome remains an area of active investigation [3, 31].
In vivo persistence of phages at day 28 post-surgery (4 days after final administration of
phage cocktail) was confirmed in representative animals treated with phage and vancomycin
(Ph+V, n = 5) by standard spot tests with 10-fold dilutions of femur homogenates onto conflu-
ent growth of the propagating strains of S. aureus (AP029 and AP030) for the lytic phages used
in the study [32]. Further support for phage accumulation and replication within the infected
knee following i.p. administration is provided by the high phage doses administered, the
reduction in joint tissue bacterial loads 7 days after administration of phages, and the absence
of significant local inflammatory responses compared to administration of vancomycin alone.
Phage replication and in vivo persistence following systemic administration with doses compa-
rable to those used in the current study has also been well-documented [2, 33]. However, we
acknowledge that there may be differences in the proportion of each of the individual phage
preparations reaching the site of infection, and the contribution of each in reducing S. aureus
numbers.
Scheduling is an important consideration for phage therapy, particularly in relation to the
impact on innate and adaptive immune responses [34, 35]. Whilst phages cannot infect nor
replicate within eukaryotic cells, they do interact and influence eukaryotic cell activity, includ-
ing immune cells. Opsonisation of bacteria with phages for example, has been shown to
increase bacterial uptake by phagocytes [34, 36]. Strategies to improve the in vivo persistence
of phages following systemic delivery are actively being investigated and include encapsulation
with polymeric microparticles and liposomes [4, 36]. Administration of phages by alternate
routes, including oral, aerosol and perioperative delivery has also shown to be effective for
treatment of chronic bacterial infections [7]. Further studies to elucidate the optimal approach
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for phage administration and the mechanisms underlying the success or failure of phage ther-
apy for biofilm-associated PJI are warranted.
The potential emergence of phage-resistant variants following phage therapy is recognised,
with bacterial strains evolving strategies to block adsorption, prevent injection of phage genetic
material and interrupt other systems used by phages to replicate [37, 38]. However, the clinical
significance of phage-resistant variants remains unclear. A number of studies have shown that
phage resistance may diminish fitness or virulence of these bacterial variants and therefore
facilitate clearance by the immune system [38]. In addition to the role of selective pressure in
emergence of bacterial resistance, phage-resistant bacterial variants can also occur spontane-
ously [38]. This was observed in the present study for S. aureus isolates recovered from bone
and implants of sham- and vancomycin-treated animals. Notably, phage therapy was not asso-
ciated with the emergence of resistant variants toward the five-phage cocktail. Indeed, the use
of therapeutic phage cocktails is recommended for this very reason: variants resistant to one
specific phage type, may remain susceptible to the others comprising the cocktail [38]. Simi-
larly, vancomycin resistance was not observed following antibiotic administration in the pres-
ent study, with MICs remaining below the MIC breakpoint for intermediate resistance [39].
Nevertheless, the mean vancomycin MIC for S. aureus strains recovered from animals in all
treatment groups was significantly higher than the parent strain, suggesting that in vivo growth
contributes to the emergence of genetic or phenotypic changes that influence vancomycin sen-
sitivity. Selection for heteroresistance of MSSA to vancomycin (hVISA) and vancomycin MIC
creep has been described for osteoarticular infections, though the clinical significance of these
variants is not well understood [40, 41]. Further work to address the scientific and therapeutic
complexities of phage therapy for the treatment of biofilm-associated PJI including dosing,
route of administration and scheduling to improve delivery and efficacy at the site of infection
is warranted.
In summary, our data support the concept of phage therapy as a safe and effective adjunct
to antibiotics for treatment of S. aureus biofilm-associated PJI following TKA. Two-stage revi-
sion is currently the gold standard for management of delayed-onset or chronic PJI, though
success rates remain suboptimal [8, 15–17]. One-stage revision is a preferred, more cost-effec-
tive approach, requiring a single surgery [42]. If phages could be used in combination with
antibiotics, antimicrobial peptides and/or biofilm-disrupting enzymes to improve eradication
of bacterial biofilms, one-stage exchanges and implant retention may be feasible. These find-
ings lay the foundation for continued translational studies to optimise phage therapy as a via-
ble adjunct for the treatment of PJI in a post-antibiotic era.
Supporting information
S1 Fig. Scoring of in vitro sensitivity of S. aureus toward StaPhage preparations. Represen-
tative images of the semi-quantitative scoring system used to assess the in vitro S. aureus sus-
ceptibility toward StaPhage preparations. 0 = no plaques, 1 =< 10 individual plaques, 2 = 11–
100 individual plaques, 3 = partial clearing, >100 plaques, 4 = clearing with several distinct
bacterial colonies within the clearance zone, 5 = complete clearing.
(TIF)
S1 Table. Clinical and haematology parameters. Body weight, body temperature, haematol-
ogy and systemic inflammation were assessed at baseline, prior to (day 5 and 20 post-surgery)
and following treatment (day 28 post-surgery) for sham-treated (Sham) animals, and those
treated with phage alone (Ph), vancomycin alone (V) and phage plus vancomycin (Ph+V).
(PDF)
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S2 Table. Phage sensitivity patterns of S. aureus isolates. Sensitivity screening of individual
phage preparations and the StaPhage cocktail was performed for S. aureus isolates recovered
from femur and titanium implants of sham-treated animals and animals treated with phage
alone (Ph), vancomycin alone (V) or combination therapy (Ph+V) at day 28 post-surgery
(n = 8 animals per group), and compared to that of the original, pre-implantation S. aureus
strain.
(PDF)
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